SCHEMBL3020271

SCHEMBL3020271

COC1Cc2sccc2C2(CCN(Cc3ccccc3)C(C#N)C2)O1

nearest known ligand 0.67

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
▸ SIGMAR1 Q99720 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3022274 0.84 — —
SCHEMBL3020216 0.83 — —
SCHEMBL12076314 0.83 — —
SCHEMBL3024571 0.82 — —
SCHEMBL3026914 0.81 — —
SCHEMBL3026100 0.81 — —
SCHEMBL3007231 0.81 ADRA2A (0.72) SIGMAR1
SCHEMBL3020030 0.75 SIGMAR1 (0.73) SIGMAR1
SCHEMBL13246656 0.73 SIGMAR1 (0.74) SIGMAR1
SCHEMBL3019159 0.72 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2170903-B1 SPIRO[PIPERIDINE-4,4' -THIENO[3, 2-C]PYRAN]DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF THE SIGMA RECEPTOR FOR THE TREATMENT OF PSYCHOSIS ESTEVE LABOR DR (ES) 2012-09-05 — — EP claimed
US-20100190813-A1 SPIRO [PIPERIDINE-4- 4' -THIENO [3,2-C] PYRAN] DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF THE SIGMA RECEPTOR FOR THE TREATMENT OF PSYCHOSIS OBERDORF CHRISTOPH 2010-07-29 — — US claimed
EP-2170903-B1 SPIRO[PIPERIDINE-4,4' -THIENO[3, 2-C]PYRAN]DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF THE SIGMA RECEPTOR FOR THE TREATMENT OF PSYCHOSIS ESTEVE LABOR DR (ES) 2012-09-05 — — EP disclosed
US-20100190813-A1 SPIRO [PIPERIDINE-4- 4' -THIENO [3,2-C] PYRAN] DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF THE SIGMA RECEPTOR FOR THE TREATMENT OF PSYCHOSIS OBERDORF CHRISTOPH 2010-07-29 — — US disclosed
EP-2170903-A1 SPIRO ÝPIPERIDINE-4, 4' -THIENO Ý3, 2-C¨PYRAN¨DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF THE SIGMA RECEPTOR FOR THE TREATMENT OF PSYCHOSIS Laboratorios Del. Dr. Esteve, S.A. (ES) 2010-04-07 — — EP disclosed
WO-2008155132-A1 SPIRO [PIPERIDINE-4, 4' -THIENO [3, 2-C] PYRAN] DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF THE SIGMA RECEPTOR FOR THE TREATMENT OF PSYCHOSIS LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2008-12-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100190813-A1 SPIRO [PIPERIDINE-4- 4' -THIENO [3,2-C] PYRAN] DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF THE SIGMA RECEPTOR FOR THE TREATMENT OF PSYCHOSIS SIGMAR1, OPRD1, OPRK1 SIGMAR1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback